|
1.
|
Vousden KH and Lane DP: P53 in health and
disease. Nat Rev Mol Cell Biol. 8:275–283. 2007. View Article : Google Scholar
|
|
2.
|
Schuler M and Green DR: Transcription,
apoptosis and p53: catch-22. Trends Genet. 2:182–187. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Vazquez A, Bond EE, Levine AJ and Bond LG:
The genetics of the p53 pathway, apoptosis and cancer therapy. Nat
Rev Drug Disc. 7:979–984. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Muller PAJ and Vousden KH: P53 mutations
in cancer. Nat Cell Biol. 15:2–8. 2013. View Article : Google Scholar
|
|
5.
|
Puca R, Nardinocchi L, Sacchi A, Rechavi
G, Givol D and D’Orazi G: HIPK2 modulates p53 activity towards
pro-apoptotic transcription. Mol Cancer. 8:1–14. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Puca R, Nardinocchi L, Starace G, Rechavi
G, Sacchi A, Givol D and D’Orazi G: Nox1 is involved in p53
deacetylation and suppression of its transcriptional activity and
apoptosis. Free Rad Biol Med. 48:1338–1346. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Arbiser JL, Petros J, Kiafter R,
Govindajaran B, McLaughlin ER, Brown LF, Cohen C, Moses M, Kilroy
S, Arnold RS and Lambeth JD: Reactive oxygen generated by Nox1
triggers the angiogenic switch. Proc Natl Acad Sci USA. 99:715–720.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Block K and Gorin Y: Aiding and abetting
roles of NOX oxidases in cellular transformation. Nat Rev Cancer.
12:627–637. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Docampo R and Moreno SN: The metabolism
and mode of action of gentian violet. Drug Metab Rev. 22:161–178.
1990. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Maley AM and Arbiser JL: Gentian Violet: A
19th century drug re-emerges in the 21st century. Exp Dermatol. Oct
7–2013. View Article : Google Scholar
|
|
11.
|
Perry BN, Govindarajan B, Bhandarkar SS,
Knaus UG, Valo M, Sturk C, Carrillo CO, Sohn A, Cerimele F, Dumont
D, Losken A, Williams J, Brown LF, Tan X, Yancopoulos GD and
Arbiser JL: Pharmacologic blockade of angiopoietin-2 is efficacious
against model hemangiomas in mice. J Invest Dermatol.
126:2316–2322. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Lapidoth M, Ben-Amitai D, Bhandarakar S,
Fried J and Arbiser JL: Efficacy of topical application of eosin
for ulcerated hemangiomas. J Am Acad Dermatol. 60:350–351. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Arbiser JL, Bips M, Seidler A, Bonner MY
and Kovach C: Combination therapy of imiquimod and gentian violet
for cutaneous melanoma metastases. J Am Acad Dermatol. 67:e81–e33.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Ingraham MA: The bacteriostatic action of
Gentian Violet and dependence on the oxidation-reduction potential.
J Bacteriol. 26:573–598. 1933.PubMed/NCBI
|
|
15.
|
Bhandarkar SS, Jaconi M, Fried LE, Bonner
MY, Lefkove B, Govindarajan B, Perry BN, Parhar R, Mackelfresh J,
Sohn A, Stouffs M, Knaus U, Yancopoulos G, Reiss Y, Benest AV,
Augustin HG and Arbiser JL: Fulvene-5 potently inhibits NAPDH
oxidase 4 and blocks the growth of endothelial tumors in mice. J
Clin Invest. 119:2359–2365. 2009.PubMed/NCBI
|
|
16.
|
Zhang X, Zheng Y, Fried LE, Du Y, Montano
SJ, Sohn A, Lefkove B, Holmgren L, Arbiser JL, Holmgren A and Lu J:
Disruption of the mitochondrial thioredoxin system as a cell death
mechanism of cationic triphenylmethanes. Free Rad Biol Med.
50:811–820. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Newick K, Cunniff B, Preston K, Held P,
Arbiser JL, Pass H, Mossmann B, Shukla A and Heintz N:
Peroxiredoxin 3 is a redox-dependent target of thiostrepton in
malignant mesothelioma cells. PloS One. 7:e394042012.PubMed/NCBI
|
|
18.
|
Puca R, Nardinocchi L, Gal H, Rechavi G,
Amariglio N, Domany E, Notterman DA, Scarsella M, Leonetti C,
Sacchi A, Blandino G, Givol D and D’Orazi G: Reversible dysfunction
of wild-type p53 following homeodomain-interacting protein kinase-2
knockdown. Cancer Res. 68:3707–3714. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Biroccio A, Del Bufalo D, Ricca A,
D’Angelo C, D’Orazi G, Sacchi A, Soddu S and Zupi G: Increase of
BCNU sensitivity by wt-p53 gene therapy in glioblastoma lines
depends on the administration schedule. Gene Ther. 6:1064–1072.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
D’Avenia P, Porrello A, Berardo M,
D’Angelo M, Soddu S, Arcangeli G, Sacchi A and D’Orazi G: TP53-gene
transfer induces hupersensitivity to low-dose of X-rays in
glioblastoma cells: a strategy to convert a radio-resistant
phenotype into a radiosensitive one. Cancer Lett. 231:102–112.
2006.PubMed/NCBI
|
|
21.
|
Komarov PG, Komarova EA, Kondratov RV,
Christov-Tselkov K, Coon JS, Chernov MV and Gudkov AV: A chemical
inhibitor of p53 that protects mice from the side effects of cancer
therapy. Science. 285:1733–1737. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Chen C and Hokayama H: High-efficiency
transformation of mammalian cells by plasmid DNA. Mol Cell Biol.
7:2745–2752. 1987.PubMed/NCBI
|
|
23.
|
Di Stefano V, Soddu S, Sacchi A and
D’Orazi G: HIPK2 contributes to PCAF-mediated p53 acetylation and
selective transactivation of p21Waf1 after non-apoptotic DNA
damage. Oncogene. 24:5431–5442. 2005.PubMed/NCBI
|
|
24.
|
Podhorecka M, Skladanowski A and Bozko P:
H2AX phosphorylation: its role in DNA damage response and cancer
therapy. J Nucl Acids ID. 9201612010.PubMed/NCBI
|
|
25.
|
Arbiser JL: Gentian violet is safe. J Am
Acad Derm. 61:3592009. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: the next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Lim SD, Sun C, Lambeth JD, Marshall F,
Amin M, Chung L, Petros JA and Arnold RS: Increased Nox1 and
hydrogen peroxide in prostate cancer. Prostate. 62:200–207. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Laurent E, McCoy JW, Macinz RA, Liu W,
Cheng G, Robine S, Papkoff J and Lambeth JD: Nox1 is over-expressed
in human colon cancers and correlates with activating mutations in
K-Ras. Int J Cancer. 123:100–107. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Chiera F, Meccia E, Degan P, Aquilina G,
Pietraforte D, Minetti M, Lambeth JD and Bignami M: Overexpression
of human NOX1 complex induces genome instability in mammalian
cells. Free Rad Biol Med. 44:332–342. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Brown CJ, Lain S, Verma CS, Fersht AR and
Lane DP: Awakening guardian angels: drugging the p53 pathway. Nat
Rev Cancer. 9:862–873. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Selivanova G and Wiman KG: Reactivation of
mutant p53: molecular mechanisms and therapeutical potential.
Oncogene. 26:2243–2254. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Oren M: Regulation of the p53 tumor
suppressor protein. J Biol Chem. 274:36031–36034. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Meek DW: Mechanisms of switching on p53: a
role for covalent modification? Oncogene. 18:7666–7675. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Hirao A, Kong YY, Matsuoka S, Wakeham A,
Ruland J, Yoshida H, Liu D, Elledge SJ and Mak TW: DNA
damage-induced activation of p53 by the checkpoint kinase Chk2.
Science. 287:1824–1827. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Hecker D, Page G, Lohrum M, Weiland S and
Scheidtmann KH: Complex regulation of the DNA-binding activity of
p53 by phosphorylation: differential effects of individual
phosphorylation sites on the interaction with different binding
motifs. Oncogene. 12:953–961. 1996.
|
